BEIJING – China has been referencing FDA and EMA drug regulations along with developing its own versions. While it has a long way to go in terms of the number of regulations and the maturity of regulatory regime, the CFDA wants any new regulations to be tailored specifically for the country’s market and to generate tangible benefits for the domestic industry.